Next Article in Journal
Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas
Previous Article in Journal
Study of the Influence of NanOx Parameters
Open AccessArticle

Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients

1
Team 4, Institute of Research on Cancer and Aging of Nice (IRCAN), Inserm U1081, CNRS UMR7284, Université Côte d’Azur, CHU de Nice, 06107 Nice Cedex 2, France
2
Laboratory of Clinical and Experimental Pathology, Université Côte d’Azur, CHU de Nice, University Hospital Federation OncoAge, 06001 Nice Cedex 1, France
3
Hospital-Integrated Biobank (BB-0033-00025), Université Côte d’Azur, CHU de Nice, University Hospital Federation OncoAge, 06001 Nice Cedex 1, France
4
Department of Pulmonary Medicine and Oncology, Université Côte d’Azur, CHU de Nice, University Hospital Federation OncoAge, 06001 Nice Cedex 1, France
5
Department of Thoracic Surgery, Université Côte d’Azur, CHU de Nice, University Hospital Federation OncoAge, 06001 Nice Cedex 1, France
*
Author to whom correspondence should be addressed.
Cancers 2018, 10(4), 88; https://doi.org/10.3390/cancers10040088
Received: 13 February 2018 / Revised: 19 March 2018 / Accepted: 20 March 2018 / Published: 21 March 2018
Background: With the integration of various targeted therapies into the clinical management of patients with advanced lung adenocarcinoma, next-generation sequencing (NGS) has become the technology of choice and has led to an increase in simultaneously interrogated genes. However, the broader adoption of NGS for routine clinical practice is still hampered by sophisticated workflows, complex bioinformatics analysis and medical interpretation. Therefore, the performance of the novel QIAGEN GeneReader NGS system was compared to an in-house ISO-15189 certified Ion PGM NGS platform. Methods: Clinical samples from 90 patients (60 Retrospectively and 30 Prospectively) with lung adenocarcinoma were sequenced with both systems. Mutations were analyzed and EGFR, KRAS, BRAF, NRAS, ALK, PIK3CA and ERBB2 genes were compared and sampling time and suitability for clinical testing were assessed. Results: Both sequencing systems showed perfect concordance for the overlapping genes. Correlation of allele frequency was r2 = 0.93 for the retrospective patients and r2 = 0.81 for the prospective patients. Hands-on time and total run time were shorter using the PGM system, while the GeneReader platform provided good traceability and up-to-date interpretation of the results. Conclusion: We demonstrated the suitability of the GeneReader NGS system in routine practice in a clinical pathology laboratory setting. View Full-Text
Keywords: next-generation sequencing; lung adenocarcinoma; molecular pathology; Ion PGM; GeneReader next-generation sequencing; lung adenocarcinoma; molecular pathology; Ion PGM; GeneReader
Show Figures

Figure 1

MDPI and ACS Style

Heeke, S.; Hofman, V.; Long-Mira, E.; Lespinet, V.; Lalvée, S.; Bordone, O.; Ribeyre, C.; Tanga, V.; Benzaquen, J.; Leroy, S.; Cohen, C.; Mouroux, J.; Marquette, C.H.; Ilié, M.; Hofman, P. Use of the Ion PGM and the GeneReader NGS Systems in Daily Routine Practice for Advanced Lung Adenocarcinoma Patients: A Practical Point of View Reporting a Comparative Study and Assessment of 90 Patients. Cancers 2018, 10, 88.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop